Revelation Biosciences Q3 net loss widens on Gemini development costs
REVB•Revelation Biosciences reported a Q3 net loss of $3.3 million, or $5.92 per share, as research and development costs increased. It ended the quarter with $9.1 million in cash and expects funds to last into Q2 2027.
1. Quarterly results
Revelation Biosciences’ Q3 net loss widened year over year to $3.3 million, with a loss per share of $5.92. Research and development expenses increased as the company advanced Gemini development, while general and administrative expenses also rose.
2. Cash and study plans
The company ended Q3 with $9.1 million in cash and expects its current funds to support operations into Q2 2027. It selected a contract research organization for its planned Gemini study in acute kidney injury and incurred costs related to that preparation.
